CIBC Bancorp USA’s CorMedix CRMD Stock Holding History

CIBC Bancorp USA’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362K	Buy	46,117 +378	+0.8%	+$2.99K	﹤0.01%	1445
2026 Q1	$311K	Buy	+45,739	New	+$338K	﹤0.01%	1400

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CIBC Bancorp USA's CRMD Position: Q2 2026 in Review

CIBC Bancorp USA increased its CorMedix (CRMD) stake by 0.83% in Q2 2026, buying an estimated $2.99K and bringing the position to 46,117 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

CIBC Bancorp USA first reported a position in CRMD in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

CIBC Bancorp USA held 46,117 shares of CorMedix worth $362K as of Q2 2026.
CIBC Bancorp USA bought 378 CorMedix shares in Q2 2026, an estimated $2.99K.
CorMedix made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1445 holding.
CIBC Bancorp USA first reported a position in CorMedix in Q1 2026 and has held it in 2 quarters since.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.